ActoGeniX (BEL)

ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics™, a novel class of biopharmaceuticals for the targeted treatment of severe gastrointestinal, metabolic diseases, immune disorders and allergies. ActoBiotics™ can be orally administered and are designed to be safer and more effective than injectable biopharmaceuticals.